In addition, PAD2 was found to be overexpressed in patients with many types of tumor tissues, such as castration-resistance prostate cancer (CRPC) (Wang et al., 2017), invasive breast ductal carcinoma, cervical squamous cell carcinoma, colon adenocarcinoma, liver hepatocellular carcinoma, lung cancer, ovarian serous papillary adenocarcinoma, and papillary thyroid carcinoma samples (McElwee et al., 2012; Guo et al., 2017). This evidence concerns the gene PADI2 and neoplasm.